Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 239

1.

Targeting Wnt Signaling via Notch in Intestinal Carcinogenesis.

Kaemmerer E, Jeon MK, Berndt A, Liedtke C, Gassler N.

Cancers (Basel). 2019 Apr 18;11(4). pii: E555. doi: 10.3390/cancers11040555. Review.

2.

Intestinal dysbiosis augments liver disease progression via NLRP3 in a murine model of primary sclerosing cholangitis.

Liao L, Schneider KM, Galvez EJC, Frissen M, Marschall HU, Su H, Hatting M, Wahlström A, Haybaeck J, Puchas P, Mohs A, Peng J, Bergheim I, Nier A, Hennings J, Reißing J, Zimmermann HW, Longerich T, Strowig T, Liedtke C, Cubero FJ, Trautwein C.

Gut. 2019 Aug;68(8):1477-1492. doi: 10.1136/gutjnl-2018-316670. Epub 2019 Mar 14.

PMID:
30872395
3.

Validation of a Nomogram Predicting Non-Sentinel Lymph Node Metastases among Patients with Breast Cancer after Primary Systemic Therapy - a transSENTINA Substudy.

Liedtke C, Görlich D, Bauerfeind I, Fehm T, Fleige B, Helms G, Lebeau A, Staebler A, Ataseven B, Denkert C, Gerber B, Heil J, Krug D, Kümmel S, Schwentner L, von Minckwitz G, Loibl S, Untch M, Kühn T.

Breast Care (Basel). 2018 Dec;13(6):440-446. doi: 10.1159/000489565. Epub 2018 Nov 6.

PMID:
30800039
4.

West German Study PlanB Trial: Adjuvant Four Cycles of Epirubicin and Cyclophosphamide Plus Docetaxel Versus Six Cycles of Docetaxel and Cyclophosphamide in HER2-Negative Early Breast Cancer.

Nitz U, Gluz O, Clemens M, Malter W, Reimer T, Nuding B, Aktas B, Stefek A, Pollmanns A, Lorenz-Salehi F, Uleer C, Krabisch P, Kuemmel S, Liedtke C, Shak S, Wuerstlein R, Christgen M, Kates RE, Kreipe HH, Harbeck N; West German Study Group PlanB Investigators.

J Clin Oncol. 2019 Apr 1;37(10):799-808. doi: 10.1200/JCO.18.00028. Epub 2019 Feb 20.

PMID:
30785826
5.

Correction to: Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial.

Nitz U, Gluz O, Christgen M, Kates RE, Clemens M, Malter W, Nuding B, Aktas B, Kuemmel S, Reimer T, Stefek A, Lorenz-Salehi F, Krabisch P, Just M, Augustin D, Liedtke C, Chao C, Shak S, Wuerstlein R, Kreipe HH, Harbeck N.

Breast Cancer Res Treat. 2019 May;175(1):265-266. doi: 10.1007/s10549-018-05105-8.

6.

Lymph Nodes in Breast Cancer - What Can We Learn from Translational Research?

Peintinger F, Reitsamer R, Smidt ML, Kühn T, Liedtke C.

Breast Care (Basel). 2018 Oct;13(5):342-347. doi: 10.1159/000492435. Epub 2018 Sep 25. Review.

7.

Systematic analysis of parameters predicting pathological axillary status (ypN0 vs. ypN+) in patients with breast cancer converting from cN+ to ycN0 through primary systemic therapy (PST).

Liedtke C, Kolberg HC, Kerschke L, Görlich D, Bauerfeind I, Fehm T, Fleige B, Helms G, Lebeau A, Stäbler A, Schmatloch S, Hausschild M, Schwentner L, von Minckwitz G, Loibl S, Untch M, Kühn T.

Clin Exp Metastasis. 2018 Dec;35(8):777-783. doi: 10.1007/s10585-018-9938-2. Epub 2018 Oct 15.

PMID:
30324492
8.

Efficacy of neoadjuvant pertuzumab in addition to chemotherapy and trastuzumab in routine clinical treatment of patients with primary breast cancer: a multicentric analysis.

Fasching PA, Hartkopf AD, Gass P, Häberle L, Akpolat-Basci L, Hein A, Volz B, Taran FA, Nabieva N, Pott B, Overkamp F, Einarson H, Hadji P, Tesch H, Ettl J, Lüftner D, Wallwiener M, Müller V, Janni W, Fehm TN, Schneeweiss A, Untch M, Pott D, Lux MP, Geyer T, Liedtke C, Seeger H, Wetzig S, Hartmann A, Schulz-Wendtland R, Belleville E, Wallwiener D, Beckmann MW, Brucker SY, Kolberg HC.

Breast Cancer Res Treat. 2019 Jan;173(2):319-328. doi: 10.1007/s10549-018-5008-3. Epub 2018 Oct 15.

PMID:
30324275
9.

Cyclin E1 and cyclin-dependent kinase 2 are critical for initiation, but not for progression of hepatocellular carcinoma.

Sonntag R, Giebeler N, Nevzorova YA, Bangen JM, Fahrenkamp D, Lambertz D, Haas U, Hu W, Gassler N, Cubero FJ, Müller-Newen G, Abdallah AT, Weiskirchen R, Ticconi F, Costa IG, Barbacid M, Trautwein C, Liedtke C.

Proc Natl Acad Sci U S A. 2018 Sep 11;115(37):9282-9287. doi: 10.1073/pnas.1807155115. Epub 2018 Aug 27.

10.

Inactivation of caspase 8 in liver parenchymal cells confers protection against murine obstructive cholestasis.

Cubero FJ, Peng J, Liao L, Su H, Zhao G, Zoubek ME, Macías-Rodríguez R, Ruiz-Margain A, Reißing J, Zimmermann HW, Gassler N, Luedde T, Liedtke C, Hatting M, Trautwein C.

J Hepatol. 2018 Dec;69(6):1326-1334. doi: 10.1016/j.jhep.2018.08.015. Epub 2018 Aug 23.

PMID:
30144553
11.

AGO Recommendations for the Diagnosis and Treatment of Patients with Advanced and Metastatic Breast Cancer: Update 2018.

Thill M, Liedtke C, Müller V, Janni W, Schmidt M; AGO Breast Committee.

Breast Care (Basel). 2018 Jul;13(3):209-215. doi: 10.1159/000489331. Epub 2018 May 22. No abstract available.

12.

AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2018.

Liedtke C, Jackisch C, Thill M, Thomssen C, Müller V, Janni W; AGO Breast Committee.

Breast Care (Basel). 2018 Jul;13(3):196-208. doi: 10.1159/000489329. Epub 2018 Jun 15. No abstract available.

13.

BRCA1/2 Mutations and Bevacizumab in the Neoadjuvant Treatment of Breast Cancer: Response and Prognosis Results in Patients With Triple-Negative Breast Cancer From the GeparQuinto Study.

Fasching PA, Loibl S, Hu C, Hart SN, Shimelis H, Moore R, Schem C, Tesch H, Untch M, Hilfrich J, Rezai M, Gerber B, Costa SD, Blohmer JU, Fehm T, Huober J, Liedtke C, Weinshilboum RM, Wang L, Ingle JN, Müller V, Nekljudova V, Weber KE, Rack B, Rübner M, von Minckwitz G, Couch FJ.

J Clin Oncol. 2018 Aug 1;36(22):2281-2287. doi: 10.1200/JCO.2017.77.2285. Epub 2018 May 23.

14.

Notch inhibition counteracts Paneth cell death in absence of caspase-8.

Jeon MK, Kaemmerer E, Schneider U, Schiffer M, Klaus C, Hennings J, Clahsen T, Ackerstaff T, Niggemann M, Schippers A, Longerich T, Sellge G, Trautwein C, Wagner N, Liedtke C, Gassler N.

Virchows Arch. 2018 Jul;473(1):71-83. doi: 10.1007/s00428-018-2368-3. Epub 2018 May 16.

PMID:
29770852
15.

Emotion recognition from faces with in- and out-group features in patients with depression.

Liedtke C, Kohl W, Kret ME, Koelkebeck K.

J Affect Disord. 2018 Feb;227:817-823. doi: 10.1016/j.jad.2017.11.085. Epub 2017 Nov 21.

PMID:
29689696
16.

Loss of Cyclin E1 attenuates hepatitis and hepatocarcinogenesis in a mouse model of chronic liver injury.

Ehedego H, Mohs A, Jansen B, Hiththetiya K, Sicinski P, Liedtke C, Trautwein C.

Oncogene. 2018 Jun;37(25):3329-3339. doi: 10.1038/s41388-018-0181-8. Epub 2018 Mar 19.

17.

Targeted Intraoperative Radiotherapy Tumour Bed Boost during Breast-Conserving Surgery after Neoadjuvant Chemotherapy - a Subgroup Analysis of Hormone Receptor-Positive HER2-Negative Breast Cancer.

Kolberg HC, Lövey G, Akpolat-Basci L, Stephanou M, Fasching P, Untch M, Hoffmann O, Bulsara M, Vaidya J, Liedtke C.

Breast Care (Basel). 2017 Oct;12(5):318-323. doi: 10.1159/000479424. Epub 2017 Sep 21.

18.

Comparison of Neoadjuvant Nab-Paclitaxel+Carboplatin vs Nab-Paclitaxel+Gemcitabine in Triple-Negative Breast Cancer: Randomized WSG-ADAPT-TN Trial Results.

Gluz O, Nitz U, Liedtke C, Christgen M, Grischke EM, Forstbauer H, Braun M, Warm M, Hackmann J, Uleer C, Aktas B, Schumacher C, Bangemann N, Lindner C, Kuemmel S, Clemens M, Potenberg J, Staib P, Kohls A, von Schumann R, Kates R, Kates R, Schumacher J, Wuerstlein R, Kreipe HH, Harbeck N.

J Natl Cancer Inst. 2018 Jun 1;110(6):628-637. doi: 10.1093/jnci/djx258.

PMID:
29228315
19.

Inhibition of Caspase-8 does not protect from alcohol-induced liver apoptosis but alleviates alcoholic hepatic steatosis in mice.

Hao F, Cubero FJ, Ramadori P, Liao L, Haas U, Lambertz D, Sonntag R, Bangen JM, Gassler N, Hoss M, Streetz KL, Reissing J, Zimmermann HW, Trautwein C, Liedtke C, Nevzorova YA.

Cell Death Dis. 2017 Oct 26;8(10):e3152. doi: 10.1038/cddis.2017.532.

20.

News from ASCO 2017.

Schmidt M, Fehm T, Liedtke C, Müller V.

Breast Care (Basel). 2017 Sep;12(4):266-268. doi: 10.1159/000480393. Epub 2017 Aug 29. No abstract available.

21.

Alcohol and Hepatocellular Carcinoma: Adding Fuel to the Flame.

Ramadori P, Cubero FJ, Liedtke C, Trautwein C, Nevzorova YA.

Cancers (Basel). 2017 Sep 25;9(10). pii: E130. doi: 10.3390/cancers9100130. Review.

22.

De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR- phase II trial: efficacy, safety, and predictive markers for 12 weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab ± weekly paclitaxel.

Nitz UA, Gluz O, Christgen M, Grischke EM, Augustin D, Kuemmel S, Braun M, Potenberg J, Kohls A, Krauss K, Stefek A, Schumacher C, Forstbauer H, Reimer T, Fischer H, Liedtke C, Wuerstlein R, Schumacher J, Kates R, Kreipe H, Harbeck N; West-German Study Group (WSG)-ADAPT Investigators.

Ann Oncol. 2017 Nov 1;28(11):2768-2772. doi: 10.1093/annonc/mdx494.

PMID:
28945833
23.

An Ultralow-Dose 1-Day Protocol With Activities Lower Than 20 MBq for the Detection of Sentinel Lymph Nodes in Breast Cancer-Experiences After 150 Cases.

Kolberg HC, Afsah S, Kuehn T, Winzer U, Akpolat-Basci L, Stephanou M, Wetzig S, Hoffmann O, Liedtke C.

Technol Cancer Res Treat. 2017 Jan 1:1533034617728862. doi: 10.1177/1533034617728862. [Epub ahead of print]

24.

AGO Recommendations for the Diagnosis and Treatment of Patients with Advanced and Metastatic Breast Cancer: Update 2017.

Thill M, Liedtke C, Solomayer EF, Müller V, Janni W, Schmidt M; AGO Breast Committee*.

Breast Care (Basel). 2017 Jul;12(3):184-191. doi: 10.1159/000477576. Epub 2017 Jun 26. No abstract available.

25.

AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2017.

Liedtke C, Thill M, Jackisch C, Thomssen C, Müller V, Janni W, Janni W; AGO Breast Committee*.

Breast Care (Basel). 2017 Jul;12(3):172-183. doi: 10.1159/000477575. Epub 2017 Jun 21. No abstract available.

26.

Initial Treatment of Patients with Primary Breast Cancer: Evidence, Controversies, Consensus: Spectrum of Opinion of German Specialists at the 15th International St. Gallen Breast Cancer Conference (Vienna 2017).

Untch M, Huober J, Jackisch C, Schneeweiss A, Brucker SY, Dall P, Denkert C, Fasching PA, Fehm T, Gerber B, Janni W, Kühn T, Lüftner D, Möbus V, Müller V, Rody A, Sinn P, Thill M, Thomssen C, Harbeck N, Liedtke C.

Geburtshilfe Frauenheilkd. 2017 Jun;77(6):633-644. doi: 10.1055/s-0043-111601. Epub 2017 Jun 28.

27.

De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early BC HER2- and Hormone Receptor-Positive Phase II Randomized Trial-Efficacy, Safety, and Predictive Markers for 12 Weeks of Neoadjuvant Trastuzumab Emtansine With or Without Endocrine Therapy (ET) Versus Trastuzumab Plus ET.

Harbeck N, Gluz O, Christgen M, Kates RE, Braun M, Küemmel S, Schumacher C, Potenberg J, Kraemer S, Kleine-Tebbe A, Augustin D, Aktas B, Forstbauer H, Tio J, von Schumann R, Liedtke C, Grischke EM, Schumacher J, Wuerstlein R, Kreipe HH, Nitz UA.

J Clin Oncol. 2017 Sep 10;35(26):3046-3054. doi: 10.1200/JCO.2016.71.9815. Epub 2017 Jul 6.

PMID:
28682681
28.

Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial.

Nitz U, Gluz O, Christgen M, Kates RE, Clemens M, Malter W, Nuding B, Aktas B, Kuemmel S, Reimer T, Stefek A, Lorenz-Salehi F, Krabisch P, Just M, Augustin D, Liedtke C, Chao C, Shak S, Wuerstlein R, Kreipe HH, Harbeck N.

Breast Cancer Res Treat. 2017 Oct;165(3):573-583. doi: 10.1007/s10549-017-4358-6. Epub 2017 Jun 29. Erratum in: Breast Cancer Res Treat. 2019 Jan 10;:.

29.

Targeting CCl4 -induced liver fibrosis by RNA interference-mediated inhibition of cyclin E1 in mice.

Bangen JM, Hammerich L, Sonntag R, Baues M, Haas U, Lambertz D, Longerich T, Lammers T, Tacke F, Trautwein C, Liedtke C.

Hepatology. 2017 Oct;66(4):1242-1257. doi: 10.1002/hep.29275. Epub 2017 Aug 26.

PMID:
28520165
30.

Breast cancer and genomic testing.

Liedtke C, Kolberg HC.

Br J Surg. 2017 Jun;104(7):799-801. doi: 10.1002/bjs.10513. Epub 2017 Mar 16. No abstract available.

PMID:
28300277
31.

Neoadjuvant Therapy for Patients with Triple Negative Breast Cancer (TNBC).

Liedtke C, Rody A.

Rev Recent Clin Trials. 2017;12(2):73-80. doi: 10.2174/1574887112666170307095945.

PMID:
28270088
32.

Attachment style moderates theory of mind abilities in depression.

Koelkebeck K, Liedtke C, Kohl W, Alferink J, Kret ME.

J Affect Disord. 2017 Apr 15;213:156-160. doi: 10.1016/j.jad.2017.02.021. Epub 2017 Feb 20.

PMID:
28236693
33.

Targeted Intraoperative Radiotherapy Tumour Bed Boost During Breast Conserving Surgery after Neoadjuvant Chemotherapy in HER2 Positive and Triple Negative Breast Cancer.

Kolberg HC, Loevey G, Akpolat-Basci L, Stephanou M, Fasching PA, Untch M, Bulsara M, Vaidya JS, Liedtke C.

Rev Recent Clin Trials. 2017;12(2):93-100. doi: 10.2174/1574887112666170201142458.

PMID:
28155607
34.

Clinical Utility of Neoadjuvant Endocrine Therapy for Hormone Receptor Positive Breast Cancer.

Kolberg HC, Aktas B, Liedtke C.

Rev Recent Clin Trials. 2017;12(2):67-72. doi: 10.2174/1574887112666170201143321. Review.

PMID:
28155606
35.

Molecular alterations in triple-negative breast cancer-the road to new treatment strategies.

Denkert C, Liedtke C, Tutt A, von Minckwitz G.

Lancet. 2017 Jun 17;389(10087):2430-2442. doi: 10.1016/S0140-6736(16)32454-0. Epub 2016 Dec 7. Review.

PMID:
27939063
36.

Neoadjuvant Chemotherapy with Docetaxel, Carboplatin and Weekly Trastuzumab Is Active in HER2-Positive Early Breast Cancer: Results after a Median Follow-Up of over 4 Years.

Kolberg HC, Akpolat-Basci L, Stephanou M, Aktas B, Hannig CV, Liedtke C.

Breast Care (Basel). 2016 Oct;11(5):323-327. Epub 2016 Oct 24.

37.

Using ultrasound and palpation for predicting axillary lymph node status following neoadjuvant chemotherapy - Results from the multi-center SENTINA trial.

Schwentner L, Helms G, Nekljudova V, Ataseven B, Bauerfeind I, Ditsch N, Fehm T, Fleige B, Hauschild M, Heil J, Kümmel S, Lebeau A, Schmatloch S, Schrenk P, Staebler A, Loibl S, Untch M, Von Minckwitz G, Liedtke C, Kühn T.

Breast. 2017 Feb;31:202-207. doi: 10.1016/j.breast.2016.11.012. Epub 2016 Nov 24.

38.

Targeted intraoperative radiotherapy tumour bed boost during breast-conserving surgery after neoadjuvant chemotherapy.

Kolberg HC, Loevey G, Akpolat-Basci L, Stephanou M, Fasching PA, Untch M, Liedtke C, Bulsara M, Vaidya JS.

Strahlenther Onkol. 2017 Jan;193(1):62-69. doi: 10.1007/s00066-016-1072-y. Epub 2016 Nov 17.

PMID:
27858093
39.

Evaluation of Local and Distant Recurrence Patterns in Patients with Triple-Negative Breast Cancer According to Age.

Radosa JC, Eaton A, Stempel M, Khander A, Liedtke C, Solomayer EF, Karsten M, Pilewskie M, Morrow M, King TA.

Ann Surg Oncol. 2017 Mar;24(3):698-704. doi: 10.1245/s10434-016-5631-3. Epub 2016 Oct 25.

40.

Systemic Therapy of Advanced/Metastatic Breast Cancer - Current Evidence and Future Concepts.

Liedtke C, Kolberg HC.

Breast Care (Basel). 2016 Aug;11(4):275-281. Epub 2016 Jul 28. Review.

41.

AGO Recommendations for the Diagnosis and Treatment of Patients with Advanced and Metastatic Breast Cancer: Update 2016.

Thill M, Liedtke C; AGO Breast Committee.

Breast Care (Basel). 2016 Jun;11(3):216-22. doi: 10.1159/000447030. Epub 2016 Jun 15. No abstract available.

42.

AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2016.

Liedtke C, Thill M; AGO Breast Committee.

Breast Care (Basel). 2016 Jun;11(3):204-14. doi: 10.1159/000446941. Epub 2016 Jun 23. No abstract available.

43.

The calcium-activated potassium channel KCa3.1 is an important modulator of hepatic injury.

Sevelsted Møller L, Fialla AD, Schierwagen R, Biagini M, Liedtke C, Laleman W, Klein S, Reul W, Koch Hansen L, Rabjerg M, Singh V, Surra J, Osada J, Reinehr R, de Muckadell OB, Köhler R, Trebicka J.

Sci Rep. 2016 Jun 29;6:28770. doi: 10.1038/srep28770.

44.

Subtypes of Triple-negative Breast Cancer Cell Lines React Differently to Eribulin Mesylate.

Bräutigam K, Mitzlaff K, Uebel L, Köster F, Polack S, Pervan M, Steinert G, Rody A, Liedtke C.

Anticancer Res. 2016 Jun;36(6):2759-66.

PMID:
27272786
45.

Keratin 23 is a stress-inducible marker of mouse and human ductular reaction in liver disease.

Guldiken N, Kobazi Ensari G, Lahiri P, Couchy G, Preisinger C, Liedtke C, Zimmermann HW, Ziol M, Boor P, Zucman-Rossi J, Trautwein C, Strnad P.

J Hepatol. 2016 Sep;65(3):552-9. doi: 10.1016/j.jhep.2016.04.024. Epub 2016 May 2.

PMID:
27151178
46.

Treatment Modification in Young Breast Cancer Patients.

Scharl A, Salterberg A, Untch M, Liedtke C, Stickeler E, Papathemelis T.

Oncol Res Treat. 2016;39(3):122-8. doi: 10.1159/000444355. Epub 2016 Feb 24. Review.

PMID:
27031253
47.

Comparison of prognostic and predictive impact of genomic or central grade and immunohistochemical subtypes or IHC4 in HR+/HER2- early breast cancer: WSG-AGO EC-Doc Trial.

Gluz O, Liedtke C, Huober J, Peyro-Saint-Paul H, Kates RE, Kreipe HH, Hartmann A, Pelz E, Erber R, Mohrmann S, Möbus V, Augustin D, Hoffmann G, Thomssen C, Jänicke F, Kiechle M, Wallwiener D, Kuhn W, Nitz U, Harbeck N; EC-Doc investigators (West German Study Group/AGO-B).

Ann Oncol. 2016 Jun;27(6):1035-40. doi: 10.1093/annonc/mdw070. Epub 2016 Feb 18.

PMID:
27022068
48.

Her2-neu score as a prognostic factor for outcome in patients with triple-negative breast cancer.

Schmidt G, Gerlinger C, Juhasz-Böss I, Stickeler E, Rody A, Liedtke C, Wimberger P, Link T, Müller E, Fehm T, Abel M, Stein S, Bohle R, Endrikat J, Solomayer EF.

J Cancer Res Clin Oncol. 2016 Jun;142(6):1369-76. doi: 10.1007/s00432-016-2146-z. Epub 2016 Mar 23.

PMID:
27008006
49.

BRCA1-like profile predicts benefit of tandem high dose epirubicin-cyclophospamide-thiotepa in high risk breast cancer patients randomized in the WSG-AM01 trial.

Schouten PC, Gluz O, Harbeck N, Mohrmann S, Diallo-Danebrock R, Pelz E, Kruizinga J, Velds A, Nieuwland M, Kerkhoven RM, Liedtke C, Frick M, Kates R, Linn SC, Nitz U, Marme F.

Int J Cancer. 2016 Aug 15;139(4):882-9. doi: 10.1002/ijc.30078. Epub 2016 May 5.

50.

West German Study Group Phase III PlanB Trial: First Prospective Outcome Data for the 21-Gene Recurrence Score Assay and Concordance of Prognostic Markers by Central and Local Pathology Assessment.

Gluz O, Nitz UA, Christgen M, Kates RE, Shak S, Clemens M, Kraemer S, Aktas B, Kuemmel S, Reimer T, Kusche M, Heyl V, Lorenz-Salehi F, Just M, Hofmann D, Degenhardt T, Liedtke C, Svedman C, Wuerstlein R, Kreipe HH, Harbeck N.

J Clin Oncol. 2016 Jul 10;34(20):2341-9. doi: 10.1200/JCO.2015.63.5383. Epub 2016 Feb 29.

PMID:
26926676

Supplemental Content

Loading ...
Support Center